Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 5,22 M
EBIT 2015 1,13 M
Net income 2015 1,04 M
Debt 2015 -
Yield 2015 -
Sales 2016 11,8 M
EBIT 2016 6,87 M
Net income 2016 6,06 M
Debt 2016 -
Yield 2016 -
P/E ratio 2015 32,08
P/E ratio 2016 5,07
Capi. / Sales 2015 5,86x
Capi. / Sales 2016 2,61x
Capitalization 30,6 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
03/30Earnings Release
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
02/04 INTELGENX TECHNOLOGIES : Announces Creation of a Scientific Advisory Board
02/04 INTELGENX TECHNOLOGIES : Announces Creation of a Scientific Advisory Board
02/03 INTELGENX TECHNOLOGIES : Strengthens Senior Management Team
02/03 INTELGENX TECHNOLOGIES : Appoints Mark Nawacki as Special Advisor
01/28 INTELGENX TECHNOLOGIES : Appoints Mark Nawacki as Special Advisor
01/28 INTELGENX TECHNOLOGIES : Appoints Mark Nawacki as Special Advisor
01/25 INTELGENX TECHNOLOGIES : Strengthens senior management team
01/22 INTELGENX TECHNOLOGIES : Strengthens Senior Management Team
More news
Sector news : Generic Pharmaceuticals
10:49a SANOFI : and Positive Planet Partnership Promote Access to Care and Quality of H..
10:30a AUROBINDO PHARMA : Q3 net profit at Rs. 535 crore
10:21a BRISTOL MYERS SQUIBB : Meet Biff: A Cancer Clinical Trial Patient
More sector news : Generic Pharmaceuticals
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions